Current Report · Items 4.01 · 8-K

Benitec Biopharma Inc.

BNTCNASDAQEQUITYCurrent

Changes in Registrant's Certifying Accountant

Filed Sep 30, 2026Accepted Sep 30, 2026, 4:08 PM EDTCIK 1808898Accession 0001193125-26-409052

Company context

Benitec Biopharma Inc. (NASDAQ: BNTC) is a clinical-stage biotechnology company developing disease-modifying genetic medicines designed to improve the lives of people with life-threatening, genetically defined diseases. The company’s proprietary “Silence and Replace” DNA-directed RNA interference (ddRNAi) platform combines RNA interference, or RNAi, with gene therapy to create medicines designed to facilitate sustained silencing of disease-causing genes and simultaneous delivery of replacement genes that restore normal cellular function following a single administration. The company’s lead investigational candidate, BB-301, is the first and only disease-modifying genetic medicine in clinical development for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD)-related dysphagia.

Current securities

BNTCNASDAQ · EQUITY · Current

Recent company filings

Registered securities in this filing

Benitec Biopharma Inc. · 8-K · Filed 2026-09-30

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, par value $0.0001

Symbol: BNTC
Exchange: NASDAQ
Classification: COMMON
Status: Current

Filing context

Context: C_80e5f82d-3655-4e20-b941-24c5b88b6ed9

Dimensions: Not supplied

Accession 000119312526409052 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 4.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 4.01Item 4.01 - Changes in Certifying Accountant

Item 4.01 Changes in Registrant’s Certifying Accountant. New Independent Registered Public Accounting Firm As previously disclosed on a Current Report on Form 8-K with the Securities and Exchange Commission that Benitec Biopharma Inc. (the “Company”) filed on September 24, 2026, the Company reported the approval of the engagement of Ernst & Young LLP (“EY”) as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2027. The engagement was subject to EY completing its client acceptance process. On September 28, 2026, EY completed its client acceptance procedures. On September 29, 2026, the Company and EY executed an engagement letter to engage EY as the Company’s independent registered public accounting firm.

Get the free weekly BCS email.